Adakveo

Adakveo

ADAKVEO ®  (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.

Resources

Administration Information

ADAKVEO is administered by IV infusion over a period of 30 minutes at Weeks 0 and 2, then every 4 weeks.

30min
30 minute infusion
1
Infusion every 4 weeks after the induction period (week 0, 2, then every 4 weeks)

Helpful Resources

Support Program

Financial Resources

Side Effects

Patient Forms

Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!

Patient Consent Form

Print & Sign

HIPAA Privacy Authorization Form

Print & Sign

Notice of Privacy Practices

Read

Patient Rights and Responsibilities

Read

Appointment Lateness and Cancelation

Read

The Sage Experience

We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.

Book Now
Book Now

Find a Sage Infusion Location Near You

We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.

Clearwater See Location

Fort Myers See Location

Orlando See Location

Sarasota See Location

Tampa See Location

The Villages (Coming 2023) See Location

At Sage Infusion, we’re committed to offering affordable treatment, with upfront pricing and no hidden costs. Here’s how we make it happen.

Explore Our Insurances